new version V2017

diabetes type 2
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

All mechanism

aleglitazar
ALEPREVENTaleglitazarplacebo - EUDRACT201200067116
ALECARDIO, 2014aleglitazarplacebo Exploratory NegativeNCT01042769
alogliptin
EXAMINE, 2013alogliptinplacebo Exploratory NegativeNCT00968708
canagliflozin
CANVAS, 2017canagliflozinplacebo Exploratory Conclusive NCT01032629
dapagliflozin
DECLARE TIMI 58, 2018dapagliflozinplacebo Exploratory - NCT01730534
empagliflozin
EMPA-REG OUTCOME, 2015empagliflozinplacebo Low risk of bias ConclusiveNCT01131676
ertugliflozin
VERTIS CV ongoing ertugliflozinplacebo - NCT01986881
exenatide
EXSCEL, 2017exenatideplacebo Low risk of bias ConclusiveNCT01144338
linagliptin
CAROLINA, 2012linagliptinglimepiride Exploratory SuggestingNCT01243424
CARMELINA ongoing linagliptinplacebo - NCT01897532
liraglutide
LEADER, 2016liraglutideplacebo Exploratory ConclusiveNCT01179048
lixisenatide
ELIXAlixisenatideplacebo Exploratory NegativeNCT01147250
pioglitazone
PROACTIVEpioglitazoneplacebo - NCT00174993
IRIS, 2016pioglitazoneplacebo - NCT00091949
saxagliptin
SAVOR TIMI, 2013saxagliptinplacebo Exploratory NegativeNCT01107886
semaglutide
SUSTAIN 6, 2016semaglutideplacebo Exploratory Conclusive NCT01720446
sitagliptin
TECOS, 2015sitagliptinplacebo Exploratory NegativeNCT00790205

angiotensin-receptor blockers

olmesartan
ORIENTolmesartanplaceboNegativeNCT00141453
ROADMAP, 2010olmesartanplacebo Low risk of bias Suggesting NCT00185159

antidiabetic drugs

gliclazide
Matthews, 2005gliclazidepioglitazone (add on MET) -
Ristic, 2006gliclazidenateglinide (add on MET) -
Khanolkar, 2008gliclaziderosiglitazone (add on MET) -
glimepiride
Charpentier, 2001glimepiride monotherapymetformin -
glimeripide
LEAD-2 (Nauck) Sulf vs pbo, 2009glimepirideplacebo (add on MET) - NCT00318461
glipizide
Feinglos, 2005glipizide GITSplacebo (add on MET) -
Nauck, 2007glipizidesitagliptin (add on MET) -
glyburide
Garber, 2006glibenclamiderosiglitazone (add on MET) -
pioglitazone
EC404pioglitazonemetformin Exploratory Negative
EC409pioglitazone + sulfonylureametformin + sulfonylurea Exploratory Negative
PNFP-026pioglitazoneplacebo Exploratory Negative
PNFP-012pioglitazoneplacebo Exploratory Negative
PNFP-001pioglitazoneplacebo Exploratory Negative
PNFP-014pioglitazone + insulinplacebo (add on insulin) Exploratory Negative
OPI-502pioglitazone + insulinplacebo (add on insulin) Exploratory Negative
PNFP-027pioglitazone + metforminplacebo (add on MET) Exploratory Negative
GLAIpioglitazonerosiglitazone Exploratory NegativeNCT00331487
PNFP-010pioglitazone + sulfonylureasulfonylurea Exploratory Negative
OPI-504pioglitazonesulfonylurea Exploratory Negative NCT00521820
EC405pioglitazonesulfonylurea Exploratory Negative
OPI-501pioglitazonesulfonylurea Exploratory Negative
OPI-520pioglitazonesulfonylurea Exploratory NegativeNCT00521742
EC410pioglitazone + metforminsulfonylurea + metformin Exploratory Negative
OPI-506pioglitazonesulfonylurea Exploratory NegativeNCT00494312
PROactive, 2005pioglitazoneplacebo Low risk of bias Suggesting NCT00174993
PERISCOPE, 2008pioglitazoneglimepiride Exploratory NegativeNCT00225277
PPAR ongoing pioglitazonestandard glucose-lowering drugs - NCT00212004
rosiglitazone
AVM100264 rosiglitazone Exploratory - NCT00359112
BRL 49653C/185 rosiglitazone Exploratory -
SB-712753/007 rosiglitazone Exploratory -
SB-712753/009 rosiglitazone Exploratory -
49653/020 rosiglitazoneglyburide Exploratory -
49653/143 rosiglitazoneglyburide Exploratory - NCT00333723
49653/079 rosiglitazoneglyburide Exploratory -
49653/080 rosiglitazoneglyburide Exploratory -
49653/097 rosiglitazoneglyburide Exploratory -
49653/137 rosiglitazoneglyburide (add on MET) Exploratory - NCT00500955
49653/093 rosiglitazonemetformin Exploratory -
49653/094 rosiglitazonemetformin Exploratory -
49653/011 rosiglitazoneplacebo Exploratory -
BRL 49653/334 rosiglitazoneplacebo Exploratory - NCT00306644
49653/128 rosiglitazoneplacebo Exploratory -
49653/134 rosiglitazoneplacebo Exploratory -
49653/136 rosiglitazoneplacebo Exploratory -
49653/330 rosiglitazoneplacebo Exploratory -
49653/331 rosiglitazoneplacebo Exploratory -
AVA100193 rosiglitazoneplacebo Exploratory -
49653/145 rosiglitazoneplacebo (add on glicazide) Exploratory -
49653/234 rosiglitazoneplacebo (add on glimepiride) Exploratory -
49653/135 rosiglitazoneplacebo (add on glipizide) Exploratory -
100684 rosiglitazoneplacebo (add on glyburide) Exploratory - NCT01045590
49653/127 rosiglitazoneplacebo (add on glyburide) Exploratory -
49653/162 rosiglitazoneplacebo (add on glyburide) Exploratory -
BRL 49653/347 rosiglitazoneplacebo (add on insulin) Exploratory - NCT00054782
49653/085 rosiglitazoneplacebo (add on insulin) Exploratory -
49653/095 rosiglitazoneplacebo (add on insulin) Exploratory -
49653/284 rosiglitazoneplacebo (add on MET) Exploratory - NCT00501020
712753/008 rosiglitazoneplacebo (add on MET) Exploratory - NCT00241605
SB-712753/002 rosiglitazoneplacebo (add on MET) Exploratory -
SB-712753/003 rosiglitazoneplacebo (add on MET) Exploratory -
49653/015 rosiglitazoneplacebo (add on SU) Exploratory -
49653/125 rosiglitazoneplacebo (add on SU) Exploratory - NCT00422955
49653/147 rosiglitazoneplacebo (add on SU) Exploratory -
49653/132 rosiglitazoneplacebo (add on SU) Exploratory -
49653/211 rosiglitazoneusual care Exploratory -
Wang, 2005rosiglitazonecontrol Exploratory -
ADOPT, 2006rosiglitazonestandard glucose-lowering drugs Exploratory NegativeNCT00279045
APPROACH, 2008rosiglitazoneglipizide Exploratory - NCT00116831
RECORD, 2009rosiglitazonestandard glucose-lowering drugs Risk of bias Negative NCT00379769

insulin secretagogues

alogliptin
Nauck, 2009alogliptinplacebo (add on MET) Exploratory Negative NCT00286442
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Simonson, 1997glipizideplacebo -
Testa, 1998glipizideplacebo -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
DeFronzo, 1995glyburidec (add on MET) -
Vray, 1995glyburideplacebo -
Erle, 1999glyburidec (add on MET) -
Marre (ass), 2002glibenclamidecontrol (add on MET) -
Blonde, 2002glyburidecontrol (add on MET) -
Garber, 2002glyburideplacebo -
Tosi, 2003glibenclamidecontrol (add on MET) -
Garber, 2003glyburidecontrol (add on MET) -
linagliptin
OwenslinagliptinMetformin + sulfonylurea - NCT00602472
Del Pratolinagliptinplacebo - NCT00621140
Taskinenlinagliptinplacebo (add on MET) - NCT00601250
Forst, 2010linagliptin - NCT00309608
Lewin, 2010linagliptinplacebo (add on SU) - NCT00819091
Gallwitz, 2012linagliptinglimepiride (add on MET) - NCT00622284
linagliptin 1218.62 ongoing linagliptin low doselinagliptin - NCT01012037
linagliptine 1218.50 ongoing linagliptinplacebo - NCT00740051
linagliptin1218.5 ongoing linagliptinplacebo - NCT00328172
linagliptin 1218.46 ongoing linagliptinplacebo - NCT00798161
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET) - NCT01215097
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD) - NCT00996658
mitiglinide
Gaomitiglinidenateglinide - NCT00461617
Kumashiro, 2007mitiglinideon top insulin glargine -
Kaku, 2009mitiglinideplacebo (on top pioglitazone) -
nateglinide
Hanefeld, 1990nateglinideplacebo -
Goldberg, 1998repaglinideplacebo -
Horton, 2000nateglinideplacebo -
Jovanovic, 2000repaglinideplacebo -
Moses, 2001nateglinideplacebo -
Marre, 2002nateglinideplacebo Exploratory -
Saloranta, 2002nateglinideplacebo -
Bech, 2003repaglinideplacebo -
Mari, 2005nateglinideplacebo -
Ristic, 2006nateglinidegliclazide (add on MET) Exploratory -
Li, 2007nategliniderepaglinide -
Li, 2009nategliniderepaglinide -
pioglitazone
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazone - NCT01183013
repaglinide
Goldberg, 1998repaglinideplacebo Exploratory -
Moses, 1999repaglinidecontrol (add on MET) Exploratory -
Landgraf, 1999repaglinideglibenclamide -
Marbury, 1999repaglinideglibenclamide -
Wolffenbuttel, 1999repaglinideglibenclamide -
Chuang, 1999repaglinideplacebo -
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin) -
Raskin, 2000repaglinideon top troglitazone -
Jovanovic, 2000repaglinideplacebo -
Madsbad, 2001repaglinideglipizide -
Raskin, 2001repaglinideon top pioglitazone -
Raskin, 2001repaglinideon top rosiglitazone -
Lund, 2007repaglinidemetformin -
saxagliptin
DeFronzo, 2009saxagliptinplacebo (add on MET)Negative NCT00121667
sitagliptin
Aschner, 2006sitagliptin monotherapyplaceboNegativeNCT00087516
Raz, 2006sitagliptin monotherapyplaceboNegative
Charbonnel, 2006sitagliptinplacebo (add on MET)NegativeNCT0086515
Rosenstock (sit on top pio vs pbo), 2006sitagliptinplacebo (on top PIO)SuggestingNCT00086502
Scott* (sit vs glipi), 2007sitagliptin 50mg bid monotherapyglipizide -
Goldstein (sit vs met), 2007sitagliptinmetformin -
Goldstein (sit+met vs met), 2007sitagliptinmetformin -
Goldstein, 2007sitagliptinplaceboNegativeNCT00103857
Hanefeld, 2007sitagliptinplaceboNegative
Scott* (sit vs pbo), 2007sitagliptin 50mg bid monotherapyplaceboNegative
Nauck, 2007sitagliptinplacebo (add on MET)NegativeNCT00094770
Scott** (sit vs pbo on top met), 2007sitagliptinplacebo (add on MET)Negative
Hermansen, 2007sitagliptinplacebo (on-top glimepiride+/- metformine)Negative
Nonaka, 2008sitagliptin monotherapyplaceboNegativeNCT00371007
vildagliptin
Ahren, 2004vildagliptinplacebo (add on MET)Negative
Ristic, 2005vildagliptin monotherapyplaceboNegative
Mimori, 2006vildagliptinplacebo -
Pratley, 2006vildagliptin monotherapyplaceboNegative
Schweizer, 2007vildagliptinmetforminNegativeNCT00099866
Rosenstock** (vilda vs pio), 2007vildagliptin monotherapypioglitazone - NCT00101803
Dejager [1], 2007vildagliptin monotherapyplaceboNegativeNCT00099905
Pi-Sunyer, 2007vildagliptin monotherapyplaceboSuggestingNCT00120536
Fonseca, 2007vildagliptinplacebo (add on insulin)SuggestingNCT00099931
Bosi, 2007vildagliptinplacebo (add on MET)NegativeNCT00099892
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NegativeNCT00101803
Garber, 2007vildagliptinplacebo (on top pioglitazone)NegativeNCT00099853
Rosenstock* (vilda vs rosi), 2007vildagliptinrosiglitazone - NCT00099918
Bolli, 2008vildagliptinpioglitazone (add on MET)NegativeNCT00237237
Scherbaum [2], 2008vildagliptinplaceboNegativeNCT00101712
Goodman, 2009vildagliptinplacebo (add on MET) Exploratory Negative
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET) Exploratory SuggestingNCT00106340

insulin secretagogues - sulfonylureas

glimeripide
Protocol 311glimepirideglibenclamide -
Charpentier (301F)glimepiridegliclazide -
Study 202glimepirideplacebo -
Kaneko, 1993glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
Draeger, 1996glimepirideglibenclamide Low risk of bias -
Dills, 1996glimepirideglyburide Exploratory -
Study 201 (Goldberg), 1996glimepirideplacebo Exploratory -
Rosenstock, 1996glimepirideplacebo -
Sonnenberg, 1997glimepiride odglimepiride bid -
Clark (301), 1997glimepirideglipizide -
Schade, 1998glimepirideplacebo -
Charpentier, 2001glimepirideplacebo (add on MET)Negative
Luis Bautista, 2003glimepirideplacebo -
Inukai, 2005glimepiridegliclazide or glibenclamide -

insulin secretagogues peptides (incretins)

albiglutide
HARMONY 7 (114179) ongoing albiglutideliraglutide - NCT01128894
exenatide
Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)Negative NCT00039026
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)Negative
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET) Low risk of bias Negative NCT00039013
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)SuggestingNCT00039013
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET) Low risk of bias Suggesting NCT00035984
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET) Low risk of bias Negative NCT00035984
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET) Risk of bias Negative NCT00099333
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET) Exploratory Suggesting NCT00099619
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+MET Risk of bias Negative NCT00082407
Kim, 2007exenatide weeklyplacebo (add on MET) Exploratory NegativeNCT00103935
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)Suggesting NCT00099320
Moretto (DOUBLONS avec druker), 2008exenatide other dosesplaceboNegativeNCT00381342
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU) Low risk of bias Suggesting NCT00324363
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD) Exploratory Negative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargine Risk of bias Suggesting NCT00641056
DURATION-2 (Bergenstal) (vs pioglitazone), 2010exenatide weeklypioglitazoneSuggestingNCT00637273
DURATION-2 (Bergenstal) (vs sitagliptin), 2010exenatide weeklysitagliptin Exploratory SuggestingNCT00637273
Buse, 2011exenatide 20µg/dplacebo (add on insulin) Low risk of bias Negative NCT00765817
H8O-MC-GWDE ongoing exenatide weeklyliraglutide - NCT01029886
liraglutide
NN2211-1796liraglutide other dosesplacebo (add on MET) - NCT00614120
Madsbad (vs Glimepiride), 2004liraglutide other dosesglimepiride Exploratory Suggesting
Madsbad (vs placebo), 2004liraglutide other dosesplaceboNegative
Harder, 2004liraglutide other dosesplacebo Exploratory -
Feinglos, 2005liraglutide other dosesmetformin Exploratory Negative
NN2211-1571 (Vilsbøll), 2007liraglutide other dosesplacebo Exploratory NegativeNCT00154401
Seino, 2008liraglutide other dosesplacebo Exploratory NegativeNCT00154414
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SU Risk of bias Suggesting NCT00518882
LEAD-3 mono 1.2mg (Garber), 2009liraglutide 1.2mgglimepiride Low risk of bias Negative NCT00294723
LEAD-3 mono 1.8mg (Garber), 2009liraglutide 1.8mgglimepiride Low risk of bias Negative NCT00294723
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009liraglutide 1.2mgglimepiride (add on MET) Low risk of bias NegativeNCT00318461
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NegativeNCT00318461
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET) Risk of bias Negative NCT00331851
LEAD-2 (Nauck) (1.2mg vs placebo), 2009liraglutide 1.2mgplacebo (add on MET)Suggesting NCT00318461
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)SuggestingNCT00318461
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU) Low risk of bias Suggesting NCT00318422
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)SuggestingNCT00318422
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)Suggesting NCT00331851
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)SuggestingNCT00333151
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU) Low risk of bias SuggestingNCT00318422
Seino, 2010liraglutide other dosesglibenclamide Low risk of bias NegativeNCT00393718
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptin Risk of bias Suggesting NCT00700817
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptin Low risk of bias Suggesting NCT00700817
EAGLE ongoing liraglutide other dosesinsulin glargine - NCT01117350
LIBRA ongoing liraglutide other dosesplacebo - NCT01270789
NN2211-1800 ongoing liraglutide other dosesplacebo - NCT00943501
NCT00978393 ongoing liraglutide other dosesplacebo - NCT00978393
NN2211-1799 ongoing liraglutide other dosesplacebo - NCT00620282
NN2211-3619 ongoing liraglutide other dosesplacebo - NCT01206101
NN8022-1923 ongoing liraglutide other dosesplacebo - NCT00781937
NN8022-1922 ongoing liraglutide other dosesplacebo - NCT01272232
NCT01234649 ongoing liraglutide other dosesplacebo (add on MET) - NCT01234649
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU) - NCT00395746
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET) - NCT01296412
lixisenatide
GetGoal-X ongoing lixisenatideexenatide Exploratory - NCT00707031
ELIXA (EFC11319) ongoing lixisenatideplacebo - NCT01147250
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin) - NCT00975286
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU) - NCT01169779
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET) - NCT00976937
taspoglutide
BC21625 ongoing taspoglutideexenatide - NCT00717457
ZC22565 ongoing taspoglutideinsulin glargine - NCT01051011
BC20965 ongoing taspoglutideinsulin glargine (add on MET) - NCT00755287
BC21893 ongoing taspoglutidepioglitazone - NCT00909597
BC20750 ongoing taspoglutideplacebo - NCT00744926
BC21713 (vs placebo) ongoing taspoglutideplacebo - NCT00754988
BC20963 ongoing taspoglutideplacebo - NCT00744367
BC22092 ongoing taspoglutideplacebo (add on MET) - NCT00823992
NC25113 ongoing taspoglutideplacebo add on standard treatment - NCT01018173

insulin sensitizer

metformin
UKPDS (vs SU or INS)metforminSU/InsulinSuggesting
Teupe, 1991metforminplaceboNegative
Campbell, 1994metforminGlipizideNegative
Kooy (HOME), 2009metforminplacebo Low risk of bias Suggesting

PPAR modulators

aleglitazar
ALECARDIOaleglitazarplacebo - NCT01042769
BC20265 ongoing aleglitazaractos - NCT00461058
BC22140 ongoing aleglitazarplacebo - NCT01042769

prevention

diet
Liao, 2002AHA 2 dietAHA 1 diet Exploratory Negative
glargine
GRACE - ORIGIN (glargine), 2012insulin glargineplacebo -
glipizide
Eriksson, 2006glipizideplacebo Exploratory Negative
metformin
Jarret, 1979lifestyle modification + metformincontrol Exploratory Negative
Sirtori, 1984metforminplacebo -
Giugliano, 1993metforminplacebo -
Crave, 1995metforminplacebo -
Charles, 1998metforminplaceboNegative
Li, 1999metforminplacebo Exploratory Negative
Morel, 1999metforminplacebo -
Charles, 2000metforminplacebo -
Moghetti, 2000metforminplacebo -
Pasquali, 2000metforminplacebo -
Freemark, 2001metforminplacebo -
Kay, 2001metforminplacebo -
Lehtovirta, 2001metforminplaceboNegative
Ng, 2001metforminplacebo -
US-DPP (metformin) (Knowler), 2002metforminplacebo Low risk of bias Negative
Fleming, 2002metforminplacebo -
Kelly, 2002metforminplacebo -
Kocak, 2002metforminplacebo -
Sturrock, 2002metforminplacebo -
EDIT (Holman), 2003metforminplacebo -
Choux, 2003metforminplacebo -
Baillargeon, 2004metforminplacebo -
Gambineri, 2004metforminplacebo -
Hoeger, 2004metforminplacebo -
Rodriguez, 2004metforminplacebo -
Rodriguez-Moctezuma, 2004metforminplaceboNegative
James, 2005metformincontrol -
Orchard, 2005metforminplaceboSuggesting
Stakos, 2005metforminplacebo -
Vitale, 2005metforminplacebo -
IDDP (Ramachandran), 2006lifestyle modification + metformincontrol Risk of bias Negative
Bridger, 2006metforminplacebo -
Srinivasan, 2006metforminplacebo -
Tang, 2006metforminplacebo -
CANOE, 2010rosiglitazone and metforminplacebo Low risk of bias SuggestingNCT00116932
nateglinide
NAVIGATOR nateglinide, 2010nateglinideplacebo Low risk of bias Negative NCT00097786
orlistat
Heymsfield, 2000orlistatplacebo Low risk of bias Negative
XENDOS (Chiasson), 2002orlistatplacebo Risk of bias Negative
ramipril
DREAM ramipril, 2006ramiprilplacebo Low risk of bias Negative NCT00095654
rosiglitazone
DREAM rosiglitazone, 2006rosiglitazoneplacebo Low risk of bias Suggesting NCT00095654
troglitazone
TRIPOD (Buchanan), 2002troglitazoneplacebo Exploratory -
US DDP troglitazone (Knowler), 2005troglitazoneplacebo Low risk of bias -
valsartan
NAVIGATOR valsartan, 2010valsartanplacebo Low risk of bias SuggestingNCT00097786
voglibose
Voglibose Ph-3, 2009vogliboseplacebo Low risk of bias SuggestingUMIN 000001109-

SGLT2 inhibitors

canagliflozin
3005: monotherapy ongoing canagliflozinplacebo -
CANTATA-D ongoing canagliflozinplacebo (add-on MET) - NCT01106677
3009: Add-on to MET ongoing canagliflozinplacebo (add-on MET) -
3008: Add-on to insulin ongoing canagliflozinplacebo (add-on MET) -
3015: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) -
3002: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) -
3012: Add-on to MET +TZD ongoing canagliflozinplacebo (add-on MET+TZD) -
3008: Add-on to SU ongoing canagliflozinplacebo (add-on SU) -
dapagliflozin
Kohandapagliflozinplacebo - NCT00972244
MB102035dapagliflozinplacebo (on top standard treatment) - NCT00976495
MB102073dapagliflozinplacebo (on top standard treatment) - NCT01137474
Weberdapagliflozinplacebo (on top standard treatment) - NCT01195662
MB102061dapagliflozinplacebo add on DPP-4 - NCT00984867
Kohandapagliflozin + merformindapagliflozin - NCT00643851
KOhandapagliflozinplacebo Low risk of bias - NCT00736879
Kohandapagliflozinplacebo - NCT00663260
Komoroski (MB102007), 2009dapagliflozinplacebo Exploratory - NCT00162305
List (MB102008), 2009dapagliflozinplacebo Exploratory - NCT00263276
Wilding (MB102009), 2009dapagliflozinplacebo (add on insulin) - NCT00357370
Ferrannini (MB102013), 2010dapagliflozinplacebo - NCT00528372
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET) Exploratory - NCT00528879
Nauck, 2011dapagliflozindlipizide add on metformin - NCT00660907
Strojek, 2011dapagliflozin + Glimepirideglimepiride - NCT00680745
Wilding, 2012dapagliflozinplacebo (add on insulin) - NCT00673231
Bolinder, 2012dapagliflozinplacebo (add on MET) - NCT00855166
Rosenstock, 2012dapagliflozinplacebo (add on TZD) - NCT00683878
Kaku, 2014dapagliflozinplacebo - NCT01294423
Yang, 2015dapagliflozin - NCT01095666
Mathieu, 2015dapagliflozinplacebo (add on MET + SAXA) - NCT01646320
Schumm-Draeger , 2015dapagliflozinplacebo (add on MET) - NCT01217892
Matthaei, 2015dapagliflozinplacebo (add on MET+SU) - NCT01392677
Cefalu, 2015dapagliflozinplacebo (on top standard treatment) - NCT01031680
Rosenstock, 2015dapagliflozinSaxagliptin (add on MET) - NCT01606007
MB102034, 2016dapagliflozin + merforminmetformin or dapa - NCT00859898
Leiter, 2016dapagliflozinplacebo (on top standard treatment) - NCT01042977
D1695C00001 ongoing dapagliflozindapagliflozin - NCT02582814
DERIVE ongoing dapagliflozinplacebo - NCT02413398
MB102-210 ongoing dapagliflozinplacebo - NCT02383238
DECLARE-TIMI 58 ongoing dapagliflozinplacebo - NCT01730534
D1693C00002 ongoing dapagliflozinplacebo - NCT01257412
D1690C00023 ongoing dapagliflozinplacebo - NCT02547935
D5553C00003 ongoing dapagliflozinplacebo (add on EXE) - NCT02229396
MB102-137 ongoing dapagliflozinplacebo (add on INS) - NCT02096705
D1683C00005 ongoing dapagliflozinplacebo (add on SAXA + MET) - NCT02681094
MB102-054 ongoing dapagliflozinplacebo (add-on MET) - NCT01095653
CV181-363 ongoing dapagliflozinsaxa (add on MET) - NCT02284893
CV181-365 ongoing dapagliflozinSaxagliptin (add on MET) - NCT02419612
0431-838 ongoing dapagliflozinSitagliptin (add on mET) - NCT02532855
empagliflozin
EMPA-REG OUTCOMEempagliflozinplacebo - NCT01131676
Kadowaki, 2013empagliflozin -
Ferrannini, 2013empagliflozinplacebo - NCT00789035
EMPA-REG MONO (Roden) vs placebo, 2013empagliflozinplacebo - NCT01177813
EMPA-REG PIO (Kovacs), 2013empagliflozinplacebo (add on MET+/-PIO) - NCT01210001
Rosenstock DOUBLON ???, 2013empagliflozinplacebo (add-on INS) -
Rosenstock, 2013empagliflozinplacebo (add-on MET) - NCT00749190
Kadowaki , 2014empagliflozin -
Ridderstrale, 2014empagliflozinGlimepiride + MET - NCT01167881
Barnett, 2014empagliflozinplacebo - NCT01164501
Rosenstock (1245.49), 2014empagliflozinplacebo (add-on INS+/-MET) - NCT01306214
EMPA-REG MET (Haring), 2014empagliflozinplacebo (add-on MET) - NCT01159600
DeFronzo, 2015empagliflozinlinagliptin (add-on MET) - NCT01422876
Lewin, 2015empagliflozinlinagliptin (monotherapy) - NCT01422876
Kadowaki, 2015empagliflozinplacebo - NCT01193218
Ross, 2015empagliflozinplacebo (add-on MET) - e2012-000905-53
Araki, 2015empagliflozinplacebo (add-on standard treatment) - NCT01368081
1275.9 ongoing empagliflozinadd-on linagliptin + MET - NCT01734785
1276.1 (bitherapy MET) ongoing empagliflozin + METMET - NCT01719003
1245.29 ongoing empagliflozinplacebo - NCT02182830
99050 ongoing empagliflozinplacebo (add on MET+/-SU) - NCT01257334
EASE-2 ongoing empagliflozinPlacebo (add-on INS) - NCT02414958
1275.19 ongoing empagliflozinplacebo add-on linagliptin - NCT02453555
saxagliptin
CV181-369 ongoing Saxagliptin/DapagliflozinGlargine insulin - NCT02551874



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons